Abstract: Provided are a negative electrode that is for use in a non-aqueous electrolyte secondary battery, includes a porous metal body as a current collector, contains a skeleton-forming agent highly infiltrated in the current collector so that it is less likely to suffer from structural degradation and provides improved cycle durability; and a non-aqueous electrolyte secondary battery including such a negative electrode. The negative electrode for use in a non-aqueous electrolyte secondary battery includes a current collector including a porous metal body; a first negative electrode material disposed in pores of the porous metal body and including a conductive aid, a binder, and a negative electrode active material including a silicon-based material; and a second negative electrode material disposed in pores of the porous metal body and including a skeleton-forming agent including a silicate having a siloxane bond.

Abstract: The purpose of the present invention is to develop a method for amplifying in vitro to a large amount of a homogenous insoluble aggregate that is equivalent to an insoluble aggregate formed in the brain of a patient. A method of producing an insoluble aggregate including TDP-43 protein and fragments thereof according to the present invention includes the steps of: (1) introducing an insoluble fraction originated from the brain of a neurodegenerative disease patient into a cell culture in which the intact TDP-43 protein can be expressed in a constitutive manner; (2) culturing the cultured cell into which the insoluble fraction has been introduced; and (3) separating an insoluble fraction from the cultured cell. Optionally, the method may additionally include a step of amplifying the insoluble aggregate of the neurodegenerative-disease-related protein in the cultured cell.

Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.

Abstract: The purpose of the present invention is to develop a method for producing a large amount of an insoluble aggregate that is equivalent to an insoluble aggregate formed in the brain of a patient. A method of producing an insoluble aggregate of a neurodegenerative-disease-related protein according to the present invention comprises the steps of: (1) introducing an insoluble fraction originated from the brain of a neurodegenerative disease patient into a cultured cell in which the neurodegenerative-disease-related protein can be expressed in a constitutive manner; (2) culturing the cultured cell into which the insoluble fraction has been introduced; and (3) extracting separating an insoluble fraction from the cultured cell. Optionally, the method may additionally comprise a step of amplifying the insoluble aggregate of the neurodegenerative-disease-related protein in the cultured cell.

Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.

Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.

Abstract: Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.